|
2007P-0003:
Issue Guidelines on Risk-Based Bioequivalence Testing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 01/04/2007
|
| 01/04/2007
|
| Private Industry
|
| Pharmaceutical Scientist
Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Safaraz K. Niazi, Ph.D.
|
|
|
|
|
| ACK1
|
| 01/04/2007
|
| 01/04/2007
|
| Federal Government
|
| FDA/DDM to Pharmaceutical
Scientist Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Lyle D. Jaffe
|
|
|
|
Top
| Up
Page last updated:
March 30, 2007
|
